High-resolution of comparative genomic hybridization improves detection of chromosomal aberrations with prognostic significance in neuroblastoma
| Authors | |
|---|---|
| Year of publication | 2006 |
| Type | Article in Proceedings |
| Conference | Europen Journal of Human Genetics |
| MU Faculty or unit | |
| Citation | |
| Field | Genetics and molecular biology |
| Keywords | neuroblastoma; high resolution comparative genomic hybridization; chromosomal aberration; prognostic factors |
| Description | Neuroblastoma (NB) is a genetically very heterogeneous pediatric malignant tumor. The clinical course of NB vary markedly. Therefore molecular and cytogenetic markers are studied as strong predictors of clinical outcome, to amnedclinical staging and aid in treatment planning. This malignancy is characterized by a broad spectrum of clinical behavior. Low-, intermediate, and high-risk groups have been defined based upon expected outcome following conventional therapy using both clinical and biological criteria. The criteria currently used to assign risk-group are as follows: Clinical stage, MYCN status, Shimada histology and DNA ploidy. Recently, other cytogenetic changes as 1p, 3p, 11q deletions and 17q rearrangements may also have prognostic value. The are a number of molecular genetic features known which are of prognostic importance in neuroblastoma - expression of different molecular markers as neurotrophin tyrosin kinase receptors (TrkA, B and C), tyrosine hydroxylase, neuroendocrine protein gene product 9,5 (PGP9,5), telomerase reverse transcriptase (hTERT) and vascular endothelial growth factor-A (VEGF-A). Some of them are already candidates stratifying markers. A global view of cytogenetic imbalances in NB patients can be detected by CGH. With recently developed high resolution (HR-CGH) method, we can find aberrations of < 10 Mb. In this study we report about the application of FISH and CGH/HR-CGH method for the detection of chromosomal imbalances in NB patients. In our work, FISH technique and CGH analyses were applied to 49 neuroblastomas of both low and high stage disease and the data were reviewed and correlated with clinical characteristics, including survival analysis. |
| Related projects: |